|

Tumor-draining lymph node-derived lymphocyte (LNL) Clinical Trials

4 actively recruiting trials

Also known as: LNL

Pipeline

Phase 1: 2Phase 1/2: 2

Top Sponsors

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University4

Indications

  • Breast Neoplasms4
  • Breast Cancer4
  • Cancer4

Other4 trials

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1/2
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.